Dexmedetomidine hydrochloride (dexmedetomidine) is a potent, highly selective alpha-2 adrenergic receptor agonist. It is mostly used for sedation in the intensive care unit (ICU). In 1999 the American Food and Drug Administration (FDA) approved it for short-term sedation and analgesia (<24 hours) in ICU. Subsequent studies have established its safety in longterm sedation with shorter times to extubation, less delirium, reduced ICU length of stay and reduced cost [1] [2] [3] [4] [5] [6] .
Core body temperature is more tightly regulated than other physiological parameters (e.g. blood pressure and heart rate). Fever (or pyrexia) and hyperthermia have been variably defined as a temperature exceeding between 37.5°C 7,8 and 38.3°C 9 .
Fever is an adaptive, physiologic response to pyrogens which adheres to an upward shift of the hypothalamic set-point. It requires an intact thermoregulatory system. Hyperthermia on the other hand, occurs through disordered central thermoregulation and does not adhere to the thermoregulatory set-point. As an unregulated response, temperature may become excessive with failure of central or peripheral mechanisms 10, 11 and may be complicated by encephalopathy, disseminated intravascular coagulopathy, liver dysfunction, rhabdomyolysis, multi-organ failure and death 12, 13 . Behavioural and autonomic defences may be impaired in ICU patients 11 , predisposing this group to hyperthermia.
In our institution, certain patients on dexmedetomidine developed high temperatures without a clear alternative cause, particularly following open heart surgery (OHS) and in those with an elevated body mass index (BMI). This led us to suspect drug fever. For the purposes of this study we chose a temperature threshold of ≥39.5°C to amplify any potential association between dexmedetomidine and hyperthermia.
The dexmedetomidine product literature lists pyrexia as a side-effect with a greater incidence (7.4%) compared with midazolam (2.5%) 14 . In the MIDEX trial, hyperthermia was more common in the dexmedetomidine arm, with an incidence of 3.2% versus 0.8% (P=0.062) with midazolam. In the PRODEX trial, the incidence of hyperthermia was 0.8% with dexmedetomidine compared to 0% with propofol 3 . Although other alpha-2 adrenergic receptor agonists such as methyldopa 15 , methylenedioxymethamphetamine (MDMA) 16 and clonidine 17 are known to cause drug-related hyperthermia, dexmedetomidine-associated hyperthermia has only been the subject of rare case reports in the literature [18] [19] [20] [21] [22] [23] [24] .
Sixty cases (10% of all adverse events) reported to the FDA regarding dexmedetomidine are related to the occurrence of hyperthermia 25 and include pyrexia, chills, neuroleptic malignant syndrome (NMS), hyperthermia, rhabdomyolysis, malignant hyperthermia, postoperative fever, multi-organ failure or sepsis. Despite these reports, clinician awareness of dexmedetomidine-associated hyperthemia remains low and recent dexmedetomidine [26] [27] [28] [29] [30] [31] reviews do not report hyperthermia as a potential adverse drug reaction.
The objective of this study was to review the association between dexmedetomidine use and hyperthermia in our cohort of ICU patients over a seven-year period. A series of cases were also analysed in patients suspected to have dexmedetomidine-associated hyperthermia.
Methods

Study setting
The study was performed at St Vincent's Hospital in Melbourne, Australia-a 400 bed, university-affiliated institution, offering a comprehensive range of medical and surgical specialties, including cardiothoracic surgery and neurosurgery. The 15-bed ICU is a closed, tertiary-level unit, which offers all standard critical care therapies.
Participants
All admissions between 1 July 2009 (when the database was implemented) until 31 May 2016 were included. The only exclusions were those patients with missing temperature data.
Data collection
Ethical permission was granted by the Quality and Risk Unit at the hospital as part of a quality assurance activity (030/16).
The study was performed using the existing electronic clinical information system (IntelliSpace Critical Care and Anesthesia [ICCA], Philips, North Ryde, New South Wales). This database is used in daily practice by hospital staff, detailing ICU admission, progress and discharge details, all bedside observations, laboratory data and drug prescriptions. Data input is primarily manual. Bedside observations imported directly to ICCA must be accepted and saved by the bedside nurse. Additional information was obtained from the hospital-based electronic record systems, Patient Master Index (PAS, Healthcare Group, CSC, Falls Church, VA, USA). PAS is the hospital record system for patient administrative data. Data is entered by authorised, trained personnel.
Patient data was extracted from ICCA via the Microsoft SQL Server database management system and imported into Microsoft Excel by the ICU clinical data analyst. Patient characteristics identified included age, gender, admission following OHS or from the operating room, Acute Physiology and Chronic Health Evaluation (APACHE) II score, invasive ventilation, renal replacement therapy (RRT), usage of dexmedetomidine, noradrenaline, neuroleptics, antidepressants and antibiotics (meropenem, vancomycin, piperacillin-tazobactam) during the ICU admission, neurological admission diagnoses (surgical and neurological APACHE III codes), Elixhauser comorbidities, APACHE III coded sepsis, proven infection whilst in ICU and BMI >35 kg/m 2 .
Hourly temperature recordings were extracted and the maximum temperature was determined during each admission. Temperature measurements were taken from central and peripheral sites including axillary, tympanic, nasopharyngeal, blood, and urinary catheters. Temperatures ≥39.5°C were selected and examined for their association with death. Those exposed to dexmedetomidine had their temporal temperature data extracted, including baseline temperature at the commencement of the infusion and the highest temperature recorded in the subsequent 24 and 48 hours. The mean delta difference was determined for all patients and a subanalysis of patients with obesity (BMI >35 kg/m 2 ) or admission post-OHS was also performed.
Univariate and multivariate analyses were performed for exposure to dexmedetomidine and reported temperatures ≥39.5°C. Confounders included in the multivariate model were chosen based on common attributable causes of temperature elevations within the critically ill population.
Continuous data were summarised as mean ± standard deviation (SD) and median ± interquartile range (IQR). Categorical variables are presented as numbers (n) and proportions (%). Differences were assessed using t-test or Mann-Whitney U test depending on normality. Calculations of differences were performed using contingency tables and odds ratios (OR) and the chi-square test or Fisher's exact test as appropriate. A P value <0.05 and associated confidence intervals (CI) of 95% were used to signify statistical significance. For the logistic regression modelling, variables with univariate significance or biological plausibility were included with the Hosmer-Lemeshow goodness-of-fit test and the area under a receiver operating characteristic (ROC) curve used to determine overall model fit. Statistical analysis software used was Stata/IC 14, 2015 (College Station, TX, USA).
Individual cases in which there was a high clinical suspicion of dexmedetomidine-associated hyperthermia were identified and reviewed. Those with a Naranjo score of 'possible' or 'probable' 32 were selected and described. The Naranjo scale is a systematic, questionnaire-based method to evaluate potential causal association in adverse drug reactions.
Results
Dexmedetomidine was first added to our hospital's formulary in August 2002 and has since become routinely used in our ICU ( Figure 1 ).
There were 9,931 individual ICU admissions between 1 July 2009 and 31 May 2016. Temperature records were available for 9,782 admissions (98.5%), of which 341 (3.5%) had temperatures ≥39.5°C. Relevant patient demographics are shown in Table 1 . In the study cohort, overall hospital mortality was 10.8% compared to 29.3% in the subgroup with temperatures ≥39.5°C. Note: % denominator refers to cohort of exposed or unexposed to dexmedetomidine. IQR, interquartile range; OHS, post-median sternotomy for cardiac surgery; BMI, body mass index; APACHE, Acute Physiology and Chronic Health Evaluation; SD, standard deviation; RRT, renal replacement therapy; ICU, intensive care unit.
Dexmedetomidine was administered in 611 admissions (6.3%) ( Figure 2 ). There was strong univariate association between temperatures ≥39.5°C and dexmedetomidine exposure (OR 4.5; 95% CI 3.4, 5.9; P <0.001) compared with those not exposed. This relationship was comparably greater in the subgroup post-OHS (OR 12.9; 95% CI 5.0, 31.6; P <0.001).
Multivariate analysis was performed in 9,651 cases (131 exclusions due to missing data). Receipt of dexmedetomidine remained significantly associated with a temperature ≥39.5°C ( Table 2) after adjustment for possible causes of high temperatures or differences in patient characteristics (OR 1.61; 95% CI 1.1, 2.3; P <0.01). Admission post-OHS was associated with reduced odds of temperature ≥39.5°C (OR 0.30; 95% CI 0.2, 0.6; P <0.001) than other admissions. However, those OHS patients who received dexmedetomidine were associated with increased odds of developing a temperature ≥39.5°C (OR 2.72; 95% CI 1.1, 6.9; P=0.035). Similarly, obesity (BMI >35 kg/m 2 ) was not associated with temperatures ≥39.5°C (OR 0.67; 95% CI 0.4, 1.1; P=0.133), but in those treated with dexmedetomidine the odds were significantly increased (OR 3.44; 95% CI 1.5, 7.9; P=0.004).
The temporal relationship between dexmedetomidine and elevated temperature was studied in 610 cases (one excluded due to missing temperature data). Across the cohort the mean temperature at the initiation of dexmedetomidine was 37.17°C (SD 0.76). At 24 hours, the mean highest recorded temperature was 37.76°C (SD 0.85), i.e. a mean increase from baseline of 0.59°C (95% CI 0.5 to 0.68; P <0.001). At 48 hours, the mean highest recorded temperature was 37.95°C (SD 0.86), i.e. a mean increase from baseline of 0.78°C Table 2 Multivariate analysis between temperature ≥39.5°C and potential confounders in all patients (n=9,651) (95% CI 0.69 to 0.88), P <0.001 (Figures 3, 4 ). For OHS patients with a BMI >35 kg/m 2 (n = 32), the mean temperature increase at 24 hours and 48 hours was 0.7°C (95% CI 0.3 to 1.1), P <0.001 and 0.91°C (0.45 to 1.36), P <0.001 respectively (see Figure 5 ). Table 3 details 11 patients with suspected dexmedetomidine-associated hyperthermia (Naranjo scores 32 of 'probable' or 'possible'). The highest fever recorded was 41.8°C. The mean age was 53 years (SD 16.7), mean APACHE II score 20 (SD 6) and just over half were male. The mean weight was 112 kg (SD 22.89). Admission diagnoses included post-OHS (four), complicated influenza or nosocomial pneumonia (three), neurosurgical procedures (two), Ludwig's angina and pancreatitis (one). Two patients died, one in ICU, the other on the ward. Three were transferred to rehabilitation, two went home and one was discharged to a nursing home.
Case summaries
Dexmedetomidine was commenced when first-line sedation was inadequate or to facilitate weaning in hyperactive delirium. Mean infusion time was 62 hours with most patients having infusions for only one or two days. Temperature increases did not appear to be a dose-related effect. Temperature resolution back to normal was prolonged post-cessation of dexmedetomidine in some cases. Figure 6 is an interrupted time-series for the 11 cases, showing the temperature trend preceding and after dexmedetomidine initiation with four-hourly averaged temperatures. The lines of identity are significantly different (P <0.05). Leukocytosis and eosinophilia were seldom significant in these patients. Creatine kinase (CK) was measured in seven patients; three had marginally high levels <1,000 U/l (normal <175 U/l) and four had levels >3,000 U/l (max=19,109 U/l). All 11 patients had positive cultures at some point during their admission, but extraordinarily high temperatures continued despite adequate antimicrobial therapy. Infectious diseases consultation was made in all cases. Usual cooling methods were generally not effective. Dantrolene was used in two cases in bolus doses and reduced the temperature in one case. Renal replacement therapy was instituted in five instances for both temperature control and acute renal failure.
Discussion
This study shows a strong temporal association that dexmedetomidine is a risk factor for hyperthermia. The association appears stronger for patients pos-OHS and those with World Health Organization Class II obesity. Dexmedetomidine itself is not a risk factor for increased mortality, but in those at risk, increases in temperature may adversely impact clinical outcomes, given that for each degree of increased temperature, mortality and morbidity increases 33 . Hyperthermia may expose patients to invasive and costly investigations, prolonged ventilation 34 and hospitalisation 35, 36 , unwarranted line changes and broad-spectrum antibiotics with resultant side-effects and bacterial resistance. Under-recognition may be a contributing factor and the true incidence may be higher than current estimations, especially with the increasing global use of dexmedetomidine.
We found a strong univariate association between dexmedetomidine exposure and a temperature ≥39.5°C. This association was shown to be independent of a number of likely confounders such as infection and antibiotic use in our multivariate analysis. The temporal correlation was studied between dexmedetomidine commencement and the subsequent 24 and 48 hours, showing a clear rise in temperature from baseline. Extremely high temperature outliers were also noted in the time periods postdexmedetomidine initiation.
Obesity and OHS were not associated with temperatures ≥39.5°C on their own; however, if exposed to dexmedetomidine, the odds increased at least threefold. This was also demonstrated in the temporal review, with more pronounced temperature elevations seen in those post-dexmedetomidine initiation compared to the general ICU population.
The risk factors for dexmedetomidine-associated hyperthermia are currently unknown. Further investigation is required to determine whether they are similar to other iatrogenic hyperthermias, such as NMS (triggers include dehydration, agitation, exhaustion, concomitant anticholinergic or antidepressant use, stress and malnutrition 37, 38 39 . Adipose tissue is a secretory organ controlling energy homeostasis 40 . It is actively involved in the regulation of immunity and inflammation 41 . Obesity is characterised by low-grade systemic inflammation and increased sympathetic activity 41, 42 . This pro-inflammatory state 43 , in concert with other organ failures or triggers may put obese patients at risk of hyperthermic complications. Dexmedetomidine-associated hyperthermia mechanisms are likely to be multifactorial with both central and peripheral determining factors. The mechanism may conceivably be different in different patients. Noradrenaline, serotonin and dopamine are the major neurotransmitters in hypothalamic regulation of body temperature 44 . Alpha-2 adrenoceptor agonists regulate release and function of these monoamines 45 and thus could alter body temperature regulation. Both clonidine 46, 47 and dexmedetomidine [48] [49] [50] alter shivering thresholds by action at the central alpha-2A adrenergic receptors. In animal studies where alpha-2A adrenoceptors were knocked out, the hypothermic effect of dexmedetomidine was attenuated 45 . Polymorphisms of the alpha-2A adrenergic receptors or drug interactions may be factors for developing hyperthermia. Alternatively, it may be an allergic or idiosyncratic reaction.
Malignant hyperthermia (MH) and NMS overlap with similar symptoms (hyperthermia, rigidity and elevated CK) and occurrence in defective skeletal muscle 37 . Both should be considered part of the differential in any fever of unknown origin 38, 51 . Dexmedetomidine-associated hyperthermia may also share similar pathophysiological mechanisms. NMS is usually triggered by medications (often at therapeutic doses 52 ) causing dopaminergic blockade with resultant hyperthermia, rigidity and hyper-metabolism. Elevated CK levels are not always present 37 . Symptoms usually persist for one to ten days 37 -some of our cases took time to defervesce after the cessation of dexmedetomidine.
We believe this is a serious and under-recognised complication in the critically ill, with only six previous case reports in the English literature. Lack of diagnostic criteria and possible incidence variability (depending on concurrent risk factors) may potentially lead to misdiagnosis (e.g. systemic inflammatory response syndrome or sepsis).
There were many limitations in this study. As an observational study only associations can be inferred. Temperature readings were not consistently measured at either core or peripheral sites. Peripheral temperature measurements are more inaccurate and likely to be lower than core temperatures. Pyrexial, septic, delirious and sicker patients are more likely to require dexmedetomidine for sedation and there is the potential for reverse causality being responsible for some of the observations seen, or the result of other unrecognised organ failures, infections, NMS, MH etc. Despite having high-quality prospectively collected data, our analysis had limited variables available for adjustment and there may be other confounders that we are unaware of. As a single-centre study there may also be other practices or patient groups particular to our ICU that have contributed to or caused the observed association. Lastly, the absolute numbers of patients exposed to dexmedetomidine are relatively small and further larger studies are required to confirm causality, prevalence, risk factors and mechanisms for dexmedetomidine-associated hyperthermia.
Strengths include this being the first study to examine the association between dexmedetomidine and elevated temperature, capturing all ICU admissions in a seven-year period. The majority of patients had temperature data available for analysis. The study also took place in a tertiary unit with a broad case-mix of both medical and surgical patients.
Conclusion
Dexmedetomidine use is independently associated with high temperatures in our intensive care cohort. We recommend considering cessation of dexmedetomidine in patients whose temperature is ≥39.5C-particularly those with risk factors such as obesity or post-OHS. Vigilance, a high degree of clinical suspicion and aggressive temperature management may be required. Mechanisms are likely multifactorial and future research should be directed at establishing prevalence, mechanisms, risk factors and other precipitants for this rare, but likely harmful, adverse event.
